JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor. In the present study, the impact of ruxolitinib treatment on cytoskeleton-related genes expression was explored. In SET2 cells, AURKA and AURKB expression/activity were downregulated in a dose-and time-dependent manner by ruxolitinib. Reversine, a multikinase inhibitor selective for aurora kinases, reduced cell viability in a dose-and/or time-dependent manner in JAK2 V617F cells. Reversine significantly increased apoptosis and mitotic catastrophe, and reduced cell proliferation and clonogenic capacity in SET2 and HEL cells. In the molecular scenario, reversine induced DNA damage and apoptosis markers, as well as, reduced AURKA and AURKB expression/activity. In SET2 cells, reversine modulated the expression of 32 out of 84 apoptosis-related genes investigated, including downregulation of antiapoptotic (BCL2, BCL2L1, and BIRC5) and upregulation of proapoptotic (BIK, BINP3, and BNIP3L) genes. Synergism experiments indicated that low dose of reversine had a potentiating effect under ruxolitinib treatment at low doses in SET2 cells. In summary, our exploratory study establishes new targets, related to the regulation of the cellular cytoskeleton, for potential pharmacological intervention in MPN. These findings indicate that AURKA and AURKB participate in the JAK2/STAT signaling pathway and contribute to the MPN phenotype.
Reversine decreases proliferation, clonogenicity, and cell cycle progression in JAK2 V617F -positive cells. Since aurora kinases are key proteins for cell cycle progression and success of cell division, we investigated the proliferation, clonogenicity, and cell cycle progression upon reversine exposure of JAK2 V617F cells. In SET2 and HEL cells, Ki-67 analysis revealed that short-time treatment with reversine significantly reduced cell proliferation ( Fig. 3A) and autonomous clonal growth capacity (Fig. 3B) , whereas long-term exposure to reversine completely inhibited colony formation in all concentration analyzed ( Supplementary Fig. 2 ). The treatment with reversine significantly induces cell cycle arrest in G 2 /M phase in both JAK2 V617F cell lines (Fig. 3C,D) .
Reversine modulates apoptosis-related genes in JAK2 V617F -positive cells.
In the molecular scenario, reversine reduces AURK activity, as observed by the reduction in histone H3 S10 phosphorylation, and increases markers of DNA damage (H2A.X phosphorylation) and apoptosis (cleaved caspase 3) ( Fig. 4A ). In SET2, but not in HEL cells, AURKA and AURKB mRNA downregulation upon the reversine was observed ( Supplementary Fig. 3 ). Corroborating these data, morphological analysis indicates the presence of mitotic catastrophe and nuclear fragmentation (Fig. 4B) .
In order to obtain additional insights about the molecular mechanisms involved in reversine-induced apoptosis, we investigated the expression of apoptosis-related genes in SET2 cells upon the treatment with reversine. A total of 32 different genes demonstrated a change in the expression of ≥1.5-fold in either direction compared to untreated cells: 6 downregulated genes (TNFRSF21, BCL2, TNFRSF10A, BIRC5, BCL2L1, and FAS) and 26 upregulated genes (CASP10, BCL10, GADD45A, CD70, TP53BP2, CASP6, BNIP3, TNFRSF9, BCL2A1, BIRC2,  NOD1, DAPK1, CASP9, BIRC3, BIK, NAIP, NOL3, CRADD, TRADD, IGF1R, BCL2L2, CD40LG, LTA, BNIP3L , HRK, and TNFRSF11B) ( Fig. 4C ; Supplementary Table 1 ). Based on the cytotoxic effect previously observed, three downregulated-antiapoptotic genes (BCL2, BCL2L1, and BIRC5) and three upregulated-proapoptotic genes (BNIP3, BNIP3L, and BIK) were selected for validation in a larger number of experiments using SET2 and HEL cells, by qPCR. In SET2, but not in HEL cells, reduced BCL2 and BIRC5 expression and increased BNIP3, BNIP3L, and BIK expression upon the treatment with reversine were observed (all p < 0.01); BCL2L1 expression was downregulated in both JAK2 V617F cell lines (p < 0.01, Fig. 4D ).
Discussion
Herein, we have investigated the effects of ruxolitinib on cytoskeleton-related genes in JAK2 V617F -driven cellular models and a modulation of AURKA and AURKB was found. A previous study reported that JAK2 V617F mutant protein activates MYC/AURKA axis, which was identified to be critical for the malignant phenotype maintenance and chemotherapy resistance in transformed-Ba/F3 cells 22 . Similarly, Wen et al. reported that AURKA is upregulated in primary cells from MPN patients and that the genetic or pharmacological inhibition of AURKA reduces bone marrow fibrosis in JAK2 V617F -and MPL W515L -driven models 23 . In STAT5B N642H -driven T cell neoplasia, AURKB is overactivated and represents potential therapeutic target 24 . Although the role of AURKA in JAK2 V617F -mediated signaling is well described in the literature 22, 23 , the functions of AURKB remain largely unknown in the context of MPN. Exploring microarray data containing gene expression profile of whole blood samples from MPN and healthy donors 25 by GEOR2 (https://www.ncbi.nlm.nih.gov/geo/geo2r/), we found that both AURKA and AURKB are upregulated in PMF patients (GEO accession GSE26049; Supplementary Fig. 4) , what corroborates previous studies 22 www.nature.com/scientificreports www.nature.com/scientificreports/ www.nature.com/scientificreports www.nature.com/scientificreports/ In the present study, AURKA and AURKB were pharmacologically targeted by reversine, a purine analogue that presents antineoplasic effects on multiple models of cancer 26 , including acute myeloid leukemia (AML) 27 , multiple myeloma 16 , and chronic myeloid leukemia (CML) 21 . Reversine reduced cell viability, proliferation, and cell cycle progression in JAK2 V617F cells. Exposure to reversine strongly inhibited autonomous growth, a characteristic that is usually associated with aggressiveness in hematological malignancies 28, 29 , in SET2 and HEL cells. A modest potentiating effect was observed with the combination of low concentrations of reversine and ruxolitinib, corroborating the hypothesis that ruxolitinib inhibits AURK-mediated signaling in MPN models.
In JAK2 V617F cells, reversine reduced AURKA and AURKB expression/activity and induced DNA damage and apoptosis markers, which was similar to the one observed for AML and CML cell lines 21, 27 . In SET2, but not in HEL cells, we observed downregulation of BCL2 and BIRC5 (antiapoptotic) and upregulation of BNIP3, BNIP3L, and BIK (proapoptotic) upon the treatment with reversine; BCL2L1 (also known as BCL-XL) was downregulated in both JAK2 V617F cells tested. These findings pave avenues to identify unrecovered molecular effects of reversine on cancer cells. It is well defined that BCL2 family plays an important role in MPN: STAT proteins are transcription factors that induce BCL2 and BCL2L1 expression, which promotes cell survival [30] [31] [32] . Thus, the modulation of the BCL2 family after exposure to reversine may contribute to a key axis to determine the potency of the drug in JAK2 V617F cells. Indeed, some differences in the potency of reversine on cell viability, proliferation, and cell progression reduction between HEL and SET2 cells were observed. Of note, HEL cells are derived from an erythroleukemia patient 33 , featuring faster growth and resistant to JAK2 inhibitors in vitro, while SET2 cells are derived from an ET patient with leukemic transformation 34 , featuring slower growth and sensibility to JAK2 inhibitors in vitro. An interesting finding is that, in HEL cells, unlike what was observed in SET2 cells, inhibition of JAK2/STAT signaling by ruxolitinib did not strongly reduce the AURKA and AURKB expression/ activation ( Supplementary Fig. 5 ), which is consistent with failure to respond to ruxolitinib in cell viability assays. Thus, in the light of our results, further studies are needed to verify whether the AURK downregulation in the context of JAK2 inhibitors could be a predictor of therapeutic response in MPN patients. Despite differences in reversine potency between HEL and SET2, our findings support results from previous studies concluding that pharmacological inhibition of aurora kinases is a promising strategy in MPN 35, 36 and provides novel mechanistic insights.
Reversine is a multikinase inhibitor which, in addition to presenting selectivity for aurora kinases, has a high inhibitory potential for MPS1 37 and JNK 38 . In view of the promising data of reversine in MPN cellular models, and the opportunity to identify new potential targets for these diseases, the effects of additional selective inhibitors for AURKA, AURKB, MPS1, and JNK were tested and all this inhibitor reduced cell viability with differences in their potencies ( Supplementary Fig. 6 ) Of note, JNK, AURK, and MPS1 signaling pathways present cross-talk contributing to cell cycle progression. JNK acts upstream to AURKB 39 , whereas AURKB potentiates MPS1 activation 40 . Thus, our findings highlight that the multitarget effects of reversine may be attractive in diseases in which this signaling axis is activated.
In summary, our exploratory study establishes new targets related to regulation of cellular cytoskeleton for potential pharmacological intervention in MPN. In JAK2 V617F cells, the multikinase inhibition, including AURKA and AURKB, by reversine, may be a strategy to block cell cycle progression and reduce cell survival. Our findings corroborate the hypothesis that aurora kinases, particularly AURKA and AURKB, participate in the JAK2/STAT signaling pathway and contribute to the MPN phenotype.
Material and Methods
RNA-seq data analysis. RNA-seq data was obtained from Meyer et al. 20 , which was deposited in GEO database (https://www.ncbi.nlm.nih.gov/geo; GEO accession GSE69827). The expression of 84 cytoskeleton-related genes in samples from naïve SET2 cells (GSM1817344, GSM1817345, and GSM1817346) and ruxolitinib-treated SET2 cells (GSM1817332, GSM1817333, and GSM1817334) was investigated. Three replicates for each condition were available. Gene expression was expressed as fold change of the mean of normalized counts of naïve SET2 cells, which was set as 1. Genes that presented mean ≥1.5-fold either direction were included in the heatmap using multiple experiment viewer (MeV) 4.9.0 software (http://mev.tm4.org). The full list of genes included, normalized counts, and relative expression values are described in Supplementary Table 2 .
Cell culture and inhibitors. SET2 cells were kindly provided by Prof. Dr. Fabíola Attié de Castro (School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil). HEL was obtained from ATCC (Philadelphia, PA, USA). SET2 and HEL cells harboring JAK2 V617F mutation were tested and authenticated by Short Tandem Repeat (STR) matching analysis using the PowerPlex ® 16 HS system (Promega, Madison, WI, USA) and the ABI 3500 Sequence Detector System (Life Technologies, Foster City, CA, USA). Cell culture conditions were performed in accordance with the recommendations of ATCC and DSMZ. All cell lines were mycoplasma-free. Ruxolitinib was obtained from InvivoGen (San Diego, CA, USA). Reversine was obtained from TargetMol (Target Molecule Corp., Boston, MA, USA). Aurora-A Inhibitor I (SML0882), AZD1152-HQPA (SML0268), NMS-P715 (475949) and SP600125 (S5567) were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Quantitative PCR (qPCR). Total RNA was obtained using TRIzol reagent (Thermo Fisher Scientific). The cDNA was synthesized from 1 µg of RNA using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific). Quantitative PCR (qPCR) was performed with an ABI 7500 Sequence Detector System using the ruxolitinib (3, 10, 30, 100, 300, and 1000 nM) alone or in combination with each other for 48 hours. Values are expressed as the percentage of viable cells for each condition relative to untreated controls. Results are shown as the mean of at least three independent experiments. www.nature.com/scientificreports www.nature.com/scientificreports/ TaqMan system for AURKA (Hs00269212.m1), AURKB (Hs00177782.m1), ATCB (4310881E-1008027), and GUS (43108881E-0905024) genes (Life Technologies) or SyberGreen System for AURKA, AURKB, BCL2, BCL2L1, BIRC5, BNIP3, BNIP3L, and BIK ( Supplementary Table 3 ). ATCB, GUS, and/or HPRT1 were the reference genes. The relative quantification value was calculated using the equation 2 −ΔΔCT . A negative 'No Template Control' was included for each primer pair.
Western blot analysis. Equal amounts of protein were used as total extracts, followed by SDS-PAGE, Western blot analysis with the indicated antibodies and imaging using the SuperSignal ™ West Dura Extended Duration Substrate System (Thermo Fisher Scientific, San Jose, CA, USA) and Gel Doc XR+ system (Bio-Rad, Hercules, CA, USA) or G:BOX Chemi XX6 gel doc systems (Syngene, Cambridge, UK). Antibodies against STAT3 (sc-7179), STAT5 (sc-835), AURKA (sc-25425), AURKB (sc-25426), phospho (p)-histone H3 S10 (sc-8659-R), and p-histone H2A.X S139 (γ-H2A.X; sc-517348) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against p-STAT3 Y705 (#9131S), p-STAT5 Y694 (#9359S), and caspase 3 (#9665) were obtained from Cell Signaling Technology (Danvers, MA, USA). Cropped gels retain important bands, but whole gel images are available in Supplementary Fig. 7 .
Cell viability assay. Cell viability was measured by methylthiazoletetrazolium (MTT) assay. SET2 (4 × 10 4 cells/well) and HEL cells (2 × 10 4 cells/well) were cultured in a 96-well plate in RPMI medium containing 10% or 20% FBS, respectively, in the presence of graded concentrations of reversine (1, 2.5, 5, 10, 25, and 50 μM) for 24, 48, and 72 hours. DMSO (Ø) was used as a negative control. IC 50 values were calculated using a nonlinear regression analysis on GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). For combined treatment analysis, SET2 and HEL cells were treated with graded doses of reversine (1, 2.5, 5, 10, 25, and 50 μM) and Western blot analysis for AURKA, AURKB, phospho(p)-histone H3 S10 , p-histone H2A.X S139 (γ-H2A.X) and Caspase 3 (total and cleaved) in total cell extracts from SET2 and HEL cells treated with graded concentrations of reversine (vehicle, 1, 2.5, 5, 10 or 25 μM) for 48 hours; membranes were reprobed with the antibody for the detection of the respective total protein or α-tubulin, and developed with the SuperSignal ™ West Dura Extended Duration Substrate system using a Gel Doc XR+ imaging system. Cropped blots are shown and full-length blots are included in Supplementary Fig. 7. (B) Immunofluorescence analysis of SET2 and HEL cells treated or not with 5 μM reversine for 24 hours, displaying α-tubulin (green) and DAPI (blue) staining. Blank and red arrows illustrate mitotic catastrophe and nuclear fragmentation, respectively. Scale bars are shown in the figure (50 μm). Bar graphs represent the quantification of morphological findings of at least 200 cells for each condition. (C) Gene expression heatmap from qPCR array analysis of SET2 cells treated with reversine (5 μM). The mRNA levels are normalized to those of vehicle-treated SET2 cells and calculated as fold change in expression; genes demonstrating ≥1.5-fold in either direction compared to vehicle-treated cells upon the treatment with reversine are included in the heatmap. Two independent experiments of each condition were used for the analysis; green indicates repressed mRNA levels and red elevated mRNA levels. (D) qPCR analysis of BCL2, BCL2L1, BIRC5, BNIP3, BNIP3L, and BIK mRNA expression in SET2 and HEL cells treated with reversine (5 μM). The dashed line represents the mean gene expression in vehicle-treated cells and bars represent the fold change in gene expression in SET2 and HEL cells treated with reversine (5 μM) compared to their respective untreated cells. The p values and cell lines are indicated in the graphs. **p < 0.01, **p < 0.001; Student t test.
